Replies to post #140466 on Biotech Values

[genisi]

GILD appears to be keeping the phase-2 data on GS-5885 (the NS5A inhibitor) under wraps

I think that GILD already has a data from several hundreds patients who have been on GS-5885 in one of those regimens, for 12 or 24 weeks. There should be a poster(s).